CTOs on the Move


 
BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bio-amber.com
  • 1250 Rene-Levesque Blvd. West Suite 4110
    Montreal, QC CAN H3B 4W8
  • Phone: 514.844.8000

Executives

Name Title Contact Details

Similar Companies

Janux Therapeutics

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Senseonics

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.

Gritstone Bio

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

BIA Separations

BIA Separations is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.